Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers, Aiming To Complete Enrollment By 1H 2026 And Potential BLA Submission In 2027
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics has started patient screening for its pivotal Phase 2 ALPHA3 trial at several cancer centers. The trial aims to offer CAR T as a first-line treatment at community cancer centers, with enrollment expected to complete by the first half of 2026 and a potential BLA submission in 2027.
July 01, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allogene Therapeutics has initiated patient screening for its Phase 2 ALPHA3 trial, which aims to offer CAR T as a first-line treatment at community cancer centers. The trial is expected to complete enrollment by the first half of 2026, with a potential BLA submission in 2027.
The initiation of patient screening for the ALPHA3 trial is a significant milestone for Allogene Therapeutics. The trial's focus on CAR T as a first-line treatment at community cancer centers could lead to a broader market for their therapy. The timeline for enrollment completion and potential BLA submission suggests a clear path forward, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100